• Whereas the gold standard in the therapy of Parkinson's disease is dopamine 5 supplementation, it fails to exert a disease-modifying effect and can be associated with 6 severe motor complications.
Introduction 31
Parkinson's disease (PD), the second most common progressive neurodegenerative disorder, 32 is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars 33 compacta (SNpc). Dopamine replacement with oral levodopa, the gold standard in PD 34 therapy, offers symptomatic relief to the patients, but it is associated with the development of 35 dyskinesias and it also fails to exert a disease-modifying effect. Levodopa-induced dyskinesia Combination therapies may offer a solution, and result in even better symptom relief. 
Kynurenines

144
The KP is the main metabolic route of tryptophan degradation. The intermediates produced in 145 this enzymatic cascade, collectively termed kynurenines,includeseveral neuroactive 146 metabolites (Fig.1) . The first step in the KP is the enzymatic degradation of tryptophan by Glutamate-mediated excitotoxicity is suggested to be involved both in the neurodegenerative 
